These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 23662928

  • 1. Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy.
    Ong DE, Kamm MA, Hartono JL, Lust M.
    J Gastroenterol Hepatol; 2013 Oct; 28(10):1595-9. PubMed ID: 23662928
    [Abstract] [Full Text] [Related]

  • 2. Phenotypic features of Crohn's disease associated with failure of medical treatment.
    Moran GW, Dubeau MF, Kaplan GG, Yang H, Seow CH, Fedorak RN, Dieleman LA, Barkema HW, Ghosh S, Panaccione R, Alberta Inflammatory Bowel Disease Consortium.
    Clin Gastroenterol Hepatol; 2014 Mar; 12(3):434-42.e1. PubMed ID: 23978351
    [Abstract] [Full Text] [Related]

  • 3. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
    Rozpondek P, Zwolińska-Wcisło M, Przybylska M, Mach T.
    Przegl Lek; 2011 Mar; 68(9):602-5. PubMed ID: 22335009
    [Abstract] [Full Text] [Related]

  • 4. Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
    Martín-de-Carpi J, Pociello N, Varea V.
    J Crohns Colitis; 2010 Nov; 4(5):594-8. PubMed ID: 21122566
    [Abstract] [Full Text] [Related]

  • 5. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG, Nieminen U, Sipponen T, Turunen U, Arkkila P, Färkkilä M.
    Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
    [Abstract] [Full Text] [Related]

  • 6. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
    Sands BE, Feagan BG, Rutgeerts P, Colombel JF, Sandborn WJ, Sy R, D'Haens G, Ben-Horin S, Xu J, Rosario M, Fox I, Parikh A, Milch C, Hanauer S.
    Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
    [Abstract] [Full Text] [Related]

  • 7. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED.
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [Abstract] [Full Text] [Related]

  • 8. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.
    Tozer P, Ng SC, Siddiqui MR, Plamondon S, Burling D, Gupta A, Swatton A, Tripoli S, Vaizey CJ, Kamm MA, Phillips R, Hart A.
    Inflamm Bowel Dis; 2012 Oct; 18(10):1825-34. PubMed ID: 22223472
    [Abstract] [Full Text] [Related]

  • 9. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
    D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S.
    Am J Gastroenterol; 2011 Feb; 106(2):199-212; quiz 213. PubMed ID: 21045814
    [Abstract] [Full Text] [Related]

  • 10. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I, Faubion WA.
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [Abstract] [Full Text] [Related]

  • 11. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
    Peyrin-Biroulet L, Salleron J, Filippi J, Reenaers C, Antunes O, Filipe V, Louis E, Hébuterne X, Roblin X.
    J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084
    [Abstract] [Full Text] [Related]

  • 12. Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients.
    Mohabbat AB, Sandborn WJ, Loftus EV, Wiesner RH, Bruining DH.
    Aliment Pharmacol Ther; 2012 Sep; 36(6):569-74. PubMed ID: 22779779
    [Abstract] [Full Text] [Related]

  • 13. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM.
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [Abstract] [Full Text] [Related]

  • 14. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
    Tursi A, Elisei W, Principi M, Inchingolo CD, Nenna R, Picchio M, Giorgio F, Ierardi E, Brandimarte G.
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
    [Abstract] [Full Text] [Related]

  • 15. Methotrexate for maintaining remission in paediatric Crohn's patients with prior failure or intolerance to thiopurines: a multicenter cohort study.
    Haisma SM, Lijftogt T, Kindermann A, Damen G, de Ridder L, Escher JC, Mearin ML, de Meij T, Hendriks D, George E, Hummel T, Norbruis O, van Rheenen P.
    J Crohns Colitis; 2015 Apr; 9(4):305-11. PubMed ID: 25656249
    [Abstract] [Full Text] [Related]

  • 16. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease.
    Walters TD, Kim MO, Denson LA, Griffiths AM, Dubinsky M, Markowitz J, Baldassano R, Crandall W, Rosh J, Pfefferkorn M, Otley A, Heyman MB, LeLeiko N, Baker S, Guthery SL, Evans J, Ziring D, Kellermayer R, Stephens M, Mack D, Oliva-Hemker M, Patel AS, Kirschner B, Moulton D, Cohen S, Kim S, Liu C, Essers J, Kugathasan S, Hyams JS, PRO-KIIDS Research Group.
    Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032
    [Abstract] [Full Text] [Related]

  • 17. Addressing current treatment challenges in Crohn's disease in real life: a physician's survey.
    Vavricka SR, Radivojevic S, Manser CN, Frei P, Burri E, Fried M, Schoepfer A, Peyrin-Biroulet L, Michetti P, Rogler G, Biedermann L.
    Dig Liver Dis; 2014 Dec; 46(12):1066-71. PubMed ID: 25169961
    [Abstract] [Full Text] [Related]

  • 18. Update on idiopathic colitides.
    Strobel S, Abreu MT.
    Curr Opin Gastroenterol; 2013 Jan; 29(1):60-5. PubMed ID: 23207597
    [Abstract] [Full Text] [Related]

  • 19. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas.
    Ng SC, Plamondon S, Gupta A, Burling D, Swatton A, Vaizey CJ, Kamm MA.
    Am J Gastroenterol; 2009 Dec; 104(12):2973-86. PubMed ID: 19755971
    [Abstract] [Full Text] [Related]

  • 20. Distinctive histopathologic phenotype in resection specimens from patients with Crohn's disease receiving anti-TNF-α therapy.
    Schaeffer DF, Walsh JC, Kirsch R, Waterman M, Silverberg MS, Riddell RH.
    Hum Pathol; 2014 Sep; 45(9):1928-35. PubMed ID: 25022570
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.